



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2012

**Adeno-associated virus type 2 modulates the host DNA damage response
induced by herpes simplex virus type 1 during co-infection**

Vogel, R ; Seyffert, M ; Strasser, R ; de Oliveira, A P ; Dresch, C ; Glauser, D L ; Jolinon, N ; Salvetti, A ; Weitzman, M D ; Fraefel, C ; Ackermann, M

DOI: <https://doi.org/10.1128/JVI.05694-11>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-50653>

Journal Article

Accepted Version

Originally published at:

Vogel, R; Seyffert, M; Strasser, R; de Oliveira, A P; Dresch, C; Glauser, D L; Jolinon, N; Salvetti, A; Weitzman, M D; Fraefel, C; Ackermann, M (2012). Adeno-associated virus type 2 modulates the host DNA damage response induced by herpes simplex virus type 1 during co-infection. *Journal of Virology*, 86(1):143-155.

DOI: <https://doi.org/10.1128/JVI.05694-11>

**1 Adeno-associated virus type 2 modulates the host DNA
2 damage response induced by herpes simplex virus type 1
3 during co-infection.**

4

5 Rebecca Vogel,¹ Michael Seyffert,¹ Regina Strasser,¹ Anna P. de Oliveira,¹
6 Christiane Dresch,¹ Daniel L. Glauser,² Nelly Jolinon,³ Anna Salvetti,³ Matthew D.
7 Weitzman,^{4†} Mathias Ackermann,¹ , and Cornel Fraefel^{1*}

8

9 ¹Institute of Virology, University of Zurich, Zurich, Switzerland. ²Division of Virology,
10 Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
11 ³INSERM U758, Ecole Normale Supérieure de Lyon, Lyon, France. ⁴The Salk
12 Institute for Biological Studies, La Jolla, CA, USA.

13

14 [†] Present address: Center for Cellular and Molecular Therapeutics, The Children's
15 Hospital of Philadelphia, PA, USA.

16

17 *Corresponding author. Mailing address: Institute of Virology, University of Zurich,
18 Winterthurerstrasse 266a, 8057 Zurich, Switzerland. Phone: +41 44 6358713, Fax:
19 +41 44 6358911, E-mail: cornel.fraefel@access.uzh.ch

20

21 Running title: HSV-1-supported AAV2 replication-induced DDR

22

23 Word count abstract:180

24 Word count text: 5616

25

26 **Abstract**

27 Adeno-associated virus type 2 (AAV2) is a human parvovirus that relies on a helper
 28 virus for efficient replication. Herpes simplex virus type 1 (HSV-1) supplies helper
 29 functions and changes the environment of the cell to promote AAV2 replication. In
 30 this study, we examined the accumulation of cellular replication and repair proteins at
 31 viral replication compartments (RCs) and the influence of replicating AAV2 on HSV-1
 32 induced DNA damage responses (DDR). We observed that the ATM kinase was
 33 activated in cells co-infected with AAV2 and HSV-1. We also found that
 34 phosphorylated ATR kinase and its cofactor ATR interacting protein (ATRIP) were
 35 recruited into AAV2 RCs, but ATR signaling was not activated. DNA-PKcs, another
 36 main kinase in the DDR, was degraded during HSV-1 infection in an ICP0-dependent
 37 manner, and this degradation was markedly delayed during AAV2 co-infection.
 38 Furthermore, we detected phosphorylation of DNA-PKcs during AAV2 but not HSV-1
 39 replication. The AAV2-mediated delay in DNA-PKcs degradation affected signaling
 40 through downstream substrates. Overall, our results demonstrate that co-infection
 41 with HSV-1 and AAV2 provokes a cellular DDR which is distinct from that induced by
 42 HSV-1 alone.

43

44 **Introduction**

45

46 Adeno-associated virus type 2 (AAV2) is a small, non-enveloped parvovirus with a
47 single-stranded DNA genome of 4.7 kb (52). In absence of a helper virus, AAV2
48 establishes a latent infection, which is characterized by site-specific integration of the
49 viral genome into the AAVS1 site on human chromosome 19 (72). In presence of a
50 helper virus, AAV2 can replicate productively in the host cell nucleus. AAV2 DNA
51 replication occurs at discrete sites in the nucleus, termed replication compartments
52 (RCs). During the course of infection, several small RCs rapidly expand and fuse to
53 large structures, which displace the cellular chromatin and fill the entire cell nucleus
54 (28, 35, 37, 79, 91). AAV2 RCs contain AAV2 proteins as well as defined helper
55 virus proteins and cellular proteins (3, 35, 63, 65, 75, 79, 90, 91). Replicating AAV2
56 has inhibitory effects on both the host cell (9, 41, 68, 71, 73, 74, 100, 101) and the
57 helper virus (5, 30, 31, 34, 40, 44, 61, 84, 100).

58

59 One of the helper viruses for AAV2 replication is herpes simplex virus type 1 (HSV-1;
60 (14)). The minimal HSV-1 helper factors for AAV2 replication from plasmid
61 substrates include the helicase-primase complex encoded by UL5, UL8, and UL52,
62 and the major DNA binding protein ICP8 (3) (90). Besides viral helper factors, the
63 fate of AAV2 replication also depends on cellular proteins. Recently, cellular proteins
64 have been identified that interact with AAV2 Rep78/68 in adenovirus (Ad) or HSV-1
65 supported AAV2 replication (63, 65). Of these, the largest functional categories
66 correspond to cellular proteins which are involved in DNA metabolism including DNA
67 replication, repair, and chromatin modification.

68

69 There is accumulating evidence that the DNA damage response (DDR) pathways
70 play central roles in viral replication (92). Controlling the DDR signaling may be a
71 mechanism to prevent apoptosis and/or stop cell cycle progression (92). For
72 example DNA damage signaling has been shown to enhance the replication of
73 autonomous parvovirus minute virus of mice (MMV), perhaps in part by promoting
74 cell cycle arrest (1). In response to DNA damage, a complex signaling network is
75 activated that includes kinase regulation, transcriptional induction, and redistribution

76 of a multitude of factors (33, 38). Depending on the extent of DNA damage, cell
77 cycle progression is stopped to repair DNA breaks or apoptosis is induced. Two
78 main pathways are classified for the repair of DNA double-strand breaks,
79 homologous recombination and non-homologous end-joining (16, 36, 99). Proteins
80 which are important for sensing DNA double-strand breaks include H2AX and the
81 Mre11/Rad50/Nbs1 (MRN) complex (for a review see (47)). The
82 phosphatidylinositol-3-kinase-like kinases (PIKKs) Ataxia Telangiectasia mutated
83 (ATM) and ATM and Rad3 related (ATR) are proximal signaling kinases that have
84 key functions in signaling transduction in homologous recombination (24, 33, 60, 66,
85 69). ATM is recruited by the MRN complex (for a review see (29)) and catalytically
86 activated through dimer dissociation and auto-phosphorylation at serine (S) 1981 (6,
87 103). Examination of ATR recruitment to sites of DNA damage revealed that binding
88 of ATR to ATRIP leads to co-localization of the ATR-ATRIP complex with replication
89 protein A (RPA)-coated single-stranded DNA (7). It is suggested that interaction of
90 topoisomerase II-binding protein 1 with the ATR-ATRIP complex induces kinase
91 activity of ATR (59). A third PIKKs, DNA-dependent protein kinase (DNA-PK)
92 belongs to the non-homologous end-joining machinery and is composed of the
93 Ku70/Ku80 hetero-dimer and the catalytic subunit of DNA-PK (DNA-PKcs). Ku70/80
94 directly recognizes DNA double-strand breaks and activates DNA-PKcs (for a review
95 see (15)). Activity of DNA-PKcs is proposed to be regulated by autophosphorylation
96 at several sites, including S2056 (19, 21). Investigation of downstream signaling via
97 PIKKs suggests that checkpoint kinase (Chk) 1 is mainly a substrate of ATR after
98 recognition of single-strand breaks and stalled-replication forks (22, 32, 53, 80, 83,
99 105), while Chk2 activation by ATM is more restricted to double-strand breaks,
100 including those induced by ionizing radiation (IR) (2, 20, 42, 43, 56, 57). However,
101 there is evidence that ATR (85, 87) and DNA-PK (50, 85) can also induce Chk2
102 phosphorylation. DNA-PK (49, 86, 88), ATR (46), and ATM (8) have all been
103 reported to induce phosphorylation of p53.

104

105 HSV-1 induces activation of a cellular DNA double-strand break response pathway
106 involving the MRN complex, ATM, p53, RPA (non-phosphorylated), and Rad51 (13,
107 51, 76, 96), while the ATR response has been reported to be inhibited (58, 94).
108 Similarly, signaling via DNA-PK is also inhibited by HSV-1 through ICP0-dependent

109 proteasomal degradation of DNA-PKcs (48, 67). It has been shown that in absence
 110 of the Ku70 subunit of the DNA-PK complex, HSV-1 replication is enhanced (81).
 111 AAV2, although not replicating in absence of a helpervirus, induces a strong DDR
 112 mediated by ATR (41). A different DDR is induced upon co-infection with a
 113 helpervirus that supports AAV2 replication; for example, during Ad supported AAV2
 114 replication, the DDR signaling is primarily mediated by DNA-PK and is independent
 115 of the MRN complex (25, 75). Furthermore, activation of ATM, Chk1, Chk2, RPA,
 116 and H2AX was also observed (25, 75). Given that DNA-PK is a key kinase in non-
 117 homologous end-joining, it seems that these events may play important roles not only
 118 in (site-specific) integration of the AAV2 genome (18, 27, 77), but also in AAV2
 119 genome replication (23). As opposed to Ad and AAV2 co-infection, the DDR induced
 120 by co-infection with HSV-1 and AAV2 have not previously been investigated. Thus,
 121 the goal of the present study was to identify cellular replication and repair proteins
 122 that accumulate at AAV2 RCs when HSV-1 is the helper virus, and to determine the
 123 effect of AAV2 on the cellular DDR signaling pathways induced by HSV-1.

124 **Materials and Methods**

125

126 **Cells.** DNA-PKcs positive (expressing one copy of DNA-PKcs) and DNA-PKcs
 127 negative HCT116 cells were kindly provided by E. Hendrickson (University of
 128 Minnesota Medical School, Minneapolis, USA) and maintained in growth medium
 129 containing Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal
 130 bovine serum (FBS), 100 units/ml penicillin G, 100 µg/ml streptomycin, and 0.25
 131 µg/ml amphotericin B (1% AB). DNA-PKcs positive (Fus1) and DNA-PKcs negative
 132 (Fus9) MO59J cells were kindly provided by T. Melendy (Department of Cellular and
 133 Molecular Biology, Roswell Park Cancer Institute, Buffalo, USA.) and cultured in 50%
 134 F10 medium/50% DMEM supplemented with 10% FBS, 1% AB, and 250 µg/ml
 135 G418. The fibroblast cells AT22 IJE-T yZ5 (expressing ATM) and AT22 IJE-T pEBS7
 136 (lacking ATM) were kind gifts from Y. Shiloh (Department of Molecular Genetics and
 137 Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel).
 138 These cells were maintained in DMEM supplemented with 10% FBS, 1% AB and 100
 139 µg/ml Hygromycin B. U2OS GW33 cells were a kind gift from P. Nghiem
 140 (Department of Medicine/Dermatology, University of Washington, Seattle, USA) and
 141 were cultured in DMEM containing 10% FBS, 1% AB, 200 µg/ml G418 and 50 µg/ml
 142 Hygromycin B. Vero cells were maintained in DMEM supplemented with 10% FBS,
 143 1% AB. All cells were maintained at 37°C in a 95% air/5% CO₂ atmosphere.

144

145 **Viruses.** HSV-1 strain F was kindly provided by B. Roizman (Marjorie B. Kovler Viral
 146 Oncology Laboratories, University of Chicago, Chicago, USA). rHSV-1 dl1403
 147 (rHSV-1ΔICP0) was kindly provided by N.D. Stow (MRC Virology Unit, University of
 148 Glasgow, Glasgow, United Kingdom), and rHSV-1vEYFP-ICP4 and rHSV-1 vECFP-
 149 ICP4 was a kind gift R.D. Everett (MRC Virology Unit, University of Glasgow,
 150 Glasgow, United Kingdom). Viruses were grown on Vero cells. HSV-1 stain F was
 151 titrated on Vero cells and rHSV-1 dl1403 was titrated on U2OS cells. AAV2 and Ad2
 152 were kindly provided by H. Buening (University of Cologne, Cologne, Germany) and
 153 U. Greber (University of Zurich, Zurich, Switzerland), respectively. Recombinant
 154 AAV2CherryRep (rAAVCR) genomes, containing the AAV2 ITR flanking the *rep*
 155 ORFs fused at its 5' terminus with the mCherry coding sequence, has been
 156 described previously (3). Recombinant AAVCR particles of AAV serotype 2 were

157 produced by transient transfection of 29356 with pDG and pAAVCR, purified on two
158 successive CsCl gradients and genome containing particles titered by Dot Blot.
159 rAAV2GFP was kindly provided by M. Linden (King's College London School of
160 Medicine, London, UK).

161

162 **Antibodies.** The following primary antibodies were used: Anti-actin (Santa Cruz
163 Biotechnology (SC) 10731; dilution WB 1:10'000), anti-ATM (Genetex 70107; dilution
164 WB: 1:1000), anti-ATM-P-S1981 (Rockland Immunochemicals (RI) 200-301-400;
165 dilution WB 1:500, IF 1:50), anti-ATR (SC-28901, dilution WB 1:1000), anti-ATR-P-
166 S428 (Cell Signaling Technology (CST) 2853, dilution WB 1:500, IF 1:200), anti-
167 ATRIP (Abcam (Ab) 19531; dilution WB 1:2000, IF 1:500), anti-Chk1 (SC 8408;
168 dilution WB 1:1000), anti-Chk1-P-S345 (CST 133D3, dilution WB 1:1000), anti-Chk2
169 (SC 5278; dilution WB: 1:1000), anti-Chk2-P-T68 (SC 16297; dilution WB/IP 1:250, IF
170 1:100), anti-DNA-PKcs (NeoMarkers M5370; dilution WB 1:500, IF 1:50, Flow
171 cytometry 1:250), anti-DNA-PKcs-P-S2056 (Ab 18192; dilution WB 1:2000, IF 1:500),
172 anti-HSV-1 ICP8 (Ab 20193; dilution WB 1:1000, IF 1:200), anti-H2AX-P-S139
173 (Millipore 05-636; dilution WB 1:500, IF 1:50), anti-Nbs1 (Novus Biologicals 100-143;
174 dilution WB 1:1000), anti-Nbs1-P-S343 (Ab 47272; dilution WB 1:500, IF 1:100), anti-
175 p53 (Ab 1101; dilution WB: 1:1000), anti-p53-P-S15 (Ab 38497 (Antibody was
176 purchased in June 2009, is not available anymore); dilution WB 1:500, IF 1:500), anti-
177 AAV2 Rep (Fitzgerald Industries 10R-A111A; dilution WB 1:200), anti-RPA32 (Bethyl
178 Laboratories (BL) A300-244A; dilution WB 1:2000, IF 1:500), anti-RPA32-P-S4/8 (BL
179 A300-245A; dilution WB 1:200, IF 1:200); anti-USP7 (CST 3277; dilution WB 1:750).
180 The following secondary antibodies were used: Rabbit anti-mouse IgG-horseradish
181 peroxidase (HRP, Sigma A9044; dilution 1:10000), goat anti-rabbit IgG-HRP (Sigma
182 A6154; dilution 1:10000), rabbit TrueBlot®, goat anti-rabbit IgG (H+L)-
183 AlexaFlour(AF)405 (Molecular Probes A31556; dilution 1:500), goat anti-rabbit IgG
184 (H+L)-AF594 (Molecular Probes A11012; dilution 1:1000), goat anti-mouse IgG
185 (H+L)-AF594 (Molecular Probes A11005; dilution 1:1000), goat anti-mouse IgG
186 (H+L)-fluorescein isothiocyanate (FITC, Southern Biotechnology 1031-02; dilution
187 1:200), goat anti-rabbit IgG (H+L)-FITC (Southern Biotechnology 4050-02; dilution
188 1:200), goat anti-mouse IgG-Cy5 (Millipore AP181S; dilution 1:500).

189

190 **Western analysis.** 10^6 HCT116 cells, 5×10^6 AT22 IJE-T, or 5×10^6 MO59J fusion
 191 cells were seeded into 6cm plates. The following day, the cells were mock-infected,
 192 infected with either AAV2 (multiplicity of infection, MOI, 2000) or HSV-1 (MOI 1.5), or
 193 co-infected with AAV2 (MOI 2000) and HSV-1 (MOI 1.5) in DMEM supplemented with
 194 2% FBS and 1% AB. Cells treated for 18 h with hydroxyurea (3 mM) served as
 195 positive control for activation of DDR proteins. After 3h, 6h, 9h, 12 h, 24 h, or 48 h,
 196 cells were trypsinized, washed once with PBS and resuspended in 200 μ l EBC-170
 197 lysis buffer (50 mM Tris-HCL, 170 mM NaCl, 0.5% Nonidet P40, protease inhibitor
 198 (Complete Mini-EDTA-free, Roche Diagnostics, Rotkreuz, Switzerland). After 30 min
 199 of incubation at 4°C under constant agitation, the suspension was centrifuged (20
 200 min at 13'200 g), the supernatant collected, mixed with 2x loading buffer (4% SDS,
 201 10% β -mercaptoethanol, 20% glycerol, 0.005% bromphenol blue, 0.125 M Tris-HCL,
 202 pH 6.8) and boiled for 10 min. Cell lysates were separated, depending on the
 203 molecular weight of the protein of interest on 8%, 10%, or 12% SDS polyacrylamide-
 204 gels and transferred to Protran nitrocellulose membranes (Protran, Whatman,
 205 Bottmingen, Switzerland). For detection of γ H2AX, proteins were separated on a
 206 12% SDS polyacrylamide-gel and transferred to a PVDF membrane with a pore size
 207 of 0.45 μ m (Amersham Hybond™-P GE Healthcare Bio-Sciences AB, Uppsala
 208 Sweden). The membranes were blocked with PBS-T (PBS containing 0.3%
 209 Tween20) supplemented with 5% non-fat dry milk for 1 h at room temperature (RT).
 210 Incubation with antibodies was carried out in PBS-T supplemented with 2.5% non-fat
 211 dry milk. Primary antibodies were incubated over night at 4°C, while secondary
 212 antibodies were incubated for 1 h at RT. Membranes were washed three times with
 213 PBS-T for 10 min after each antibody incubation step. HRP-conjugated secondary
 214 antibodies were detected with ECL detection reagent (ECL Western blotting analysis
 215 systems; GE Healthcare, Zurich, Switzerland). The membranes were exposed to
 216 chemiluminescent detection films (Roche Diagnostics, Rotkreuz, Switzerland).
 217 Detection of α -actin served as loading control of the lysate.

218
 219 **Fluorescence-activated cell sorting (FACS) and Western analysis.** 6.6×10^6
 220 AT22IJE-T cells were seeded into 10 cm cell culture dishes. Cells were mock-
 221 infected, infected with rHSV-1vECFP-ICP4 (MOI 2 or 4), or co-infected with rHSV-
 222 1vECFP-ICP4 (MOI 2 or 4) and rAAV2CR (MOI 4000). Cells positive for mCherry

(rAAV2) or ICP4-ECFP (HSV-1) were sorted and prepared for Western analysis as described above. The same number of mock-infected and HU treated cells (3mM, 18hpi) were used as controls.

226

Immunoprecipitation. AT22 IJE-T cells (90'000) were seeded into 6-well plates. The next day, cells were mock-infected, infected with either AAV2 (MOI 2000) or HSV-1 (MOI 1.5), or co-infected with AAV2 (MOI 2000) and HSV-1 (MOI 1.5) in DMEM supplemented with 2% FBS and 1% AB. After 24 h, cells were trypsinized, washed once with PBS, and resuspended in 200 μ l EBC-170 lysis buffer containing the primary antibody. After incubation for 2 h at 4°C under constant agitation, 30 μ l Protein A Sepharose CL-4B (GE Healthcare, Zurich, Switzerland) were added and incubated for 2 h at 4°C under constant agitation. Then, sepharose beads were pelleted and the supernatant was collected as loading and infection controls. The pellet was washed twice with PBS for 15 min at 4°C under constant agitation, and protein was eluted using 20-40 μ l of a 4 M urea solution (pH 7.5). After 10 min incubation at 4°C under constant agitation, beads were pelleted, and the supernatant was collected. Samples were analyzed by Western blotting as described above; however, for detection of immunoprecipitated proteins, the secondary antibody rabbit IgG TrueBlot® (Anti-Rabbit IgG HRP, eBioscience, San Diego, CA, USA) was used, which preferentially detects the non-reduced form of rabbit IgG over the reduced, SDS-denatured form of IgG.

244

Immunofluorescence analysis. HCT116 cells (5×10^4), AT22 IJE-T cells ($7,5 \times 10^4$), or MO59J fusion cells ($7,5 \times 10^4$) were seeded onto cover slips (12 mm \varnothing , Glaswarenfabrik Karl Hecht GmbH&Co KG, Sondheim, Germany) in 24-well plates. The next day, cells were mock-infected, infected with HSV-1 (MOI 1.5), or co-infected with rAAV2CR (MOI 250) and either HSV-1 (MOI 1.5), rHSV-1dl1403 (MOI 0.9) or Ad2 (MOI 12). UV-exposed cells (10 J/m²) or hydroxyurea (HU, 3mM) treated cells served as positive control for activation of DDR proteins. After 24 h, cells were washed once with cold PBS and fixed with 3.7% formaldehyde in PBS for 15 min at RT. The fixation process was stopped with 0.1 M glycine for 10 min at RT. Cells were washed twice with cold PBS. For permeabilization, cells were treated for 2 min with pre-cooled acetone (-20°C) and washed three times with PBS. Cells were

256 blocked for 30 min with 3% BSA in PBS. For staining, cells were incubated with
 257 antibodies diluted in PBS-BSA (3%) in a humidified chamber at RT in the dark.
 258 Cover slips were placed on droplets (40 μ l) of primary antibody solution. After
 259 incubation for 1 h, cells were washed three times with PBS. DAPI (4',6' diamidino-2-
 260 phenylindole) staining was performed together with the secondary antibody staining.
 261 For this, DAPI (0.5 μ g/ml) and the secondary antibody were diluted in PBS-BSA
 262 (3%). After incubation for 1h at RT in the dark, cells were washed three times with
 263 PBS and once with H₂O. Cover slips were embedded in Glycergel (DakoCytomation,
 264 Carpinteria, USA) containing DABCO (26 mg/ml, Fluka, Sigma-Aldrich Chemie
 265 GmbH, Munich, Germany), and cells were observed using a confocal laser scanning
 266 microscope (CLSM, Leica TCS SP2 AOBS, Leica Microsystems, Wetzlar, Germany).
 267 To prevent crosstalk between the channels for the different fluorochromes, all
 268 channels were recorded separately and fluorochromes with longer wavelengths were
 269 recorded first. Images from CLSM were deconvolved with Huygenes Essential
 270 2.6.0p1 software (Scientific Volume Imaging, Hilversum, Netherlands) and processed
 271 using Imaris 5.0.1 (Bitplane AG, Zurich, Switzerland).

272

273 **Flow cytometry.** The day before infection, 10⁶ HCT116 cells were seeded into 6 cm
 274 tissue culture plates. The cells were mock-infected, infected with rHSV-1vEYFP-
 275 ICP4 (MOI 1.5), or co-infected with AAV2 (MOI 250), rAAV2GFP (MOI 250), and
 276 HSV-1 (MOI 1.5) in DMEM supplemented with 2% FCS and 1% AB, and incubated
 277 for 20 h at 37°C in a 5%CO₂ atmosphere. Cells were trypsinized and washed once
 278 with PBS. For fixation and staining, the BD Cytfix/Cytoperm™ Plus Kit (BD
 279 Biosciences) was used according to the manufacturer's instructions. Flow cytometry
 280 was performed on a FACScalibur (Becton-Dickinson). DNA-PKcs-contents were
 281 analyzed in HSV-1-infected cells positive for EYFP-ICP4 (rHSV-1 encoded) and in
 282 co-infected cells positive for EGFP (rAAV encoded). A minimum of 80'0000 events
 283 were scored for each sample. The mean fluorescence intensity (MFI) of cell-
 284 populations was determined using Flowjo software (Flowjo Version 8.6.3, Stanford
 285 University, Stanford, CA, USA).

286 Results

287

288 **Activation of primary DNA damage markers Nbs1 and H2AX upon virus**
 289 **infection.** We compared the DDR of cells infected with HSV-1 alone or co-infected
 290 with AAV2. As we have previously observed that at low MOI, HSV-1 supported
 291 AAV2 RCs are not detectable before approximately 18 hpi, we analyzed the cells for
 292 up to 48 hpi.

293 The overall levels of Nbs1 were not altered by virus infection (Fig. 1A). However,
 294 Nbs1 was phosphorylated upon infection with HSV-1 alone or co-infection with AAV2
 295 (Fig. 1B); moreover, phosphorylated Nbs1-P-S343 co-localized with AAV2 RCs and
 296 with HSV-1 RCs (Fig. 2A). Nbs1 expression was also examined in AT22 IJE-T and
 297 HCT116 cells with similar results (data not shown). In HCT116 cells, HSV-1 and co-
 298 infection induced phosphorylation was also indicated by shifted Nbs1 bands (data not
 299 shown). In addition, H2AX was found to be phosphorylated (Fig. 1A) and to surround
 300 HSV-1 supported AAV2 RCs (Fig. 2B). As previously observed H2AX also
 301 surrounded HSV-1 RCs (Fig. 2B (94)).

302

303

304 **Co-infection with AAV2 and HSV-1 induces the phosphorylation of ATM and**
 305 **ATR.** Previous studies revealed that ATM-mediated signaling is induced (51, 76, 96)
 306 and that ATR-mediated signaling is blocked in HSV-1 infected cells (58, 94). To
 307 examine the activity of these two PIKKs in cells co-infected with HSV-1 and AAV2,
 308 we first determined their phosphorylation status by Western blot and
 309 immunofluorescence analysis. While total ATM levels were similar in virus-infected
 310 cells and mock-infected cells (Fig. 1A), ATM-dependent staining with an antibody
 311 generated to auto-phosphorylated ATM was detected only in cells infected with HSV-
 312 1 alone or co-infected with AAV2 (Fig. 1B) and, in these cells, co-localized with HSV-
 313 1 and AAV2 RCs (Fig. 3A). As this antibody detects other phosphorylated targets of
 314 ATM such as 53BP1, this data only demonstrates that the staining requires ATM
 315 activity but does not necessarily represent ATM itself.

316 Total ATR levels were also comparable in virus-infected cells and mock-infected
 317 cells (Fig. 1A), but phosphorylated ATR-P-S428 was present only in cells infected
 318 with either HSV-1 or AAV2 alone or co-infected with both viruses (Fig. 1A), and it co-

319 localized with approximately 85% of HSV-1 RCs and approximately 87% of AAV2
 320 RCs (Fig. 3B). The observed phosphorylation of ATR in cells infected with HSV-1
 321 alone was surprising, as it appeared to be in contrast to previous studies which did
 322 not find HSV-1-induced activation of ATR (58, 94). We therefore further investigated
 323 the phosphorylation/activation of ATR by: (i) testing the specificity of the ATR-P-S428
 324 antibody (70) (ii) monitoring ATRIP, a protein that is important for the recruitment of
 325 ATR to sites of DNA damage (89, 106) and (iii) analyzing the phosphorylation status
 326 of the ATR target Chk1. The results of these experiments can be summarized as
 327 follows: (i) Immunoprecipitation with an ATR specific antibody resulted in ATR-P-
 328 S428 specific bands in cells infected with HSV-1 and/or AAV2, but not in mock-
 329 infected cells (Fig. S1A). (ii) ATRIP was detected both in mock-infected cells and
 330 virus-infected cells (Fig. 1A), where it co-localized with AAV2 and HSV-1 RCs (Fig.
 331 3C). (iii) Western analysis revealed no phosphorylation of the ATR target Chk1 at
 332 S345 (Fig S1B) and S317 (data not shown) in infected cells. Concluding from the
 333 results above, it seems that although ATR is phosphorylated in infected cells, the
 334 kinase is not activated and therefore not able to transmit DDR signaling via its
 335 downstream target Chk1. Supporting this, Nam et al. (62) recently showed that
 336 phosphorylation of ATR on S428 is not indicative of ATR activity and cannot be
 337 inhibited by the commonly used ATR inhibitor caffeine. Moreover, Liu et al. reported
 338 that the mutation of S428 to A428 did not prevent phosphorylation of Chk1 in
 339 response to replicative stress (54).

340
 341

342 **HSV-1 ICP0 dependent degradation of DNA-PKcs is delayed during co-infection**
 343 **with AAV2.** HSV-1 ICP0 is known to induce proteasomal degradation of DNA-PKcs
 344 (48, 67), which together with Ku70 and Ku80 forms DNA-PK, the third main PIKK
 345 besides ATM and ATR (reviewed in (55)). Consistent with these reports, our
 346 Western blot results displayed loss of DNA-PKcs by 48 h after infection with HSV-1
 347 or co-infection with HSV-1 and AAV2 (Fig. 1A). Accordingly, at the single cell level,
 348 DNA-PKcs was not detected simultaneously with either the HSV-1 immediate-early
 349 protein ICP0 or the HSV-1 early protein ICP8 in cells infected with HSV-1 alone.
 350 However, DNA-PKcs was readily detected in cells infected with rHSV-1ΔICP0 (Fig.
 351 4A). Interestingly, immunofluorescence analysis revealed that DNA-PKcs co-

352 localized with the HSV-1 proteins ICP0 and ICP8 in 80% and 76% of AAVRCs,
 353 respectively (Fig. 4B). This indicates that HSV-1 ICP0-mediated DNA-PKcs
 354 degradation in co-infected cells is not as efficient as in the cells that are infected with
 355 HSV-1 alone, even if intensity of DNA-PKcs staining in large AAV RCs is decreased
 356 compared to small AAV RCs (Fig. 4B). This possibility was further investigated by
 357 flow cytometry data. Cells infected with HSV-1 or co-infected with HSV-1 and AAV2
 358 were identified using rHSV-1 and rAAV expressing ICP4-EYFP or EGFP,
 359 respectively. Similar to the results obtained with wtHSV-1 (strain F), DNA-PKcs was
 360 degraded also in cells infected with the autofluorescent recombinant HSV-1 (strain17;
 361 Fig. 4C). By contrast, the fluorescence intensity of DNA-PKcs staining in cells co-
 362 infected with wtHSV-1 and AAV2 was at the same level as that in mock-infected cells
 363 (Fig. 4C). At the chosen MOIs, the ratio of cells that show AAV RCs at 24 hpi is only
 364 approximately 10%, while 24 h after infection with HSV-1 alone, more than 40% of
 365 the cells contain HSV-1 RCs. This may explain why in the Western analysis of total
 366 cell lysates shown in Figure 1, the degradation of DNA-PKcs appeared equally
 367 efficient in HSV-1 infected cells and in co-infected cells, while on the single cell level
 368 (Fig. 4, B and C) DNA-PKcs degradation appeared to be less efficient in co-infected
 369 cells.

370 To further examine this observation, we performed Western analysis of sorted cells at
 371 22 and 26 hpi (Fig. 4D and E). For this, cells were infected with rHSV-1 ICP4-ECFP
 372 or co-infected with rAAVCR and rHSV-1 ICP4-ECFP. HSV-1 infected cells were
 373 sorted based on the expression of ICP4-ECFP and cells that contain replicating rAAV
 374 RCs were sorted based on the expression of mCherry-Rep. Sorted mock-infected
 375 cells served as control. Mock-infected and HU treated cells served as activation
 376 control for DNA-PKcs. Quantification of the Western blot shown in Fig. 4 D, revealed
 377 3-times higher levels of DNA-PKcs at 22 hpi during AAV replication as compared to
 378 cells infected with HSV-1 alone (Fig. 4D). At 26 hpi, the intensity of the DNA-PKcs
 379 staining was also decreased in co-infected cells compared to 22 hpi, but still
 380 approximately 2-times higher than in cells infected with HSV-1 alone at 26 hpi.
 381 Moreover, phosphorylation of DNA-PKcs at S2056 was detected only in cells co-
 382 infected with both viruses (Fig. 4, E and F), however pDNA-PKcs-levels decreased
 383 also in co-infected cells over time (Fig. 4E). Staining for cellular deubiquitinase
 384 ubiquitin specific peptidase 7 (USP7) at 24 hpi, which is another known target of

385 HSV-1 ICP0-induced proteasomal degradation (12), revealed that the AAV-mediated
386 delay of the ICP0 function was specific for DNA-PKcs, as the degradation of USP7
387 was equally efficient in cells infected with HSV-1 alone and in co-infected cells (Fig.
388 4F).

389

390 Next, we analyzed the localization of DNA-PKcs-P-S2056 within infected cells. As
391 positive and negative controls we co-infected DNA-PKcs-positive cells and DNA-
392 PKcs-deficient cells with Ad and AAV2 which are known to activate and recruit DNA-
393 PKcs into RCs (75). While DNA-PKcs-P-S2056 staining was readily detected in cells
394 co-infected with AAV2 and either Ad2 or HSV-1, where it also co-localized with AAV2
395 RCs, we did not observe staining in cells that contained HSV-1 RCs (Fig. 4G).

396

397

398 **Phosphorylation of Chk2 and p53.** To explore a potential DNA-PK-mediated
399 signaling to downstream targets in co-infected cells, we assessed virus induced
400 phosphorylation of Chk2 and p53 in normal cells and in cells defective for either
401 DNA-PKcs (MO59J Fus9) or ATM (AT22 IJE-T pEBS7). HSV-1 has previously been
402 shown to induce the phosphorylation of Chk2 in an ATM-dependent manner (51, 76).
403 Our results are in line with these reports as in normal cells (data not shown) and in
404 DNA-PKcs-deficient cells (Fig. 5A), Chk2 was phosphorylated at 24 h after infection
405 with HSV-1, and this occurred also in cells co-infected with HSV-1 and AAV2.
406 However, in ATM-deficient cells, Chk2 was phosphorylated only in cells co-infected
407 with both viruses but not in cells infected with HSV-1 alone (Fig. 5, B). This suggests
408 that in these cells, Chk2 phosphorylation was possibly facilitated by the AAV2-
409 mediated delayed degradation of DNA-PKcs. Also consistent with previous
410 observations, we detected that HSV-1 (13) and AAV2 (68) induced the stabilization
411 of p53 (Fig. 1C). Additionally, we observed that p53 was phosphorylated at S15 in
412 cells infected with either HSV-1 or AAV2, or co-infected with both viruses (Fig. 1C),
413 and p53-P-S15 was recruited into both HSV-1 RCs and AAV2 RCs (data not shown).
414 p53-P-S15 was also detected in DNA-PKcs-deficient cells infected with HSV-1 alone
415 or co-infected with HSV-1 and AAV2 (Fig. 5A); in these cells phosphorylation is likely
416 ATM-mediated. However, as opposed to the situation in normal cells infected with
417 AAV2 alone, p53-P-S15 was not detected in DNA-PKcs-deficient cells infected with

418 AAV2 alone (Fig. 5A), indicating that in absence of the helpervirus, AAV2 induced
 419 phosphorylation of p53 is DNA-PK-dependent. In ATM-deficient cells, p53 was
 420 phosphorylated only when cells were infected with rHSV-1ΔICP0 or co-infected with
 421 AAV2 and HSV-1 (Fig. 5C), but not in cells infected with HSV-1 alone (Fig. 5C),
 422 indicating again that in co-infected cells p53 phosphorylation was supported by the
 423 delayed degradation of DNA-PKcs.

424

425

426 **Phosphorylation of RPA.** The trimeric RPA complex composed of RPA70, RPA32,
 427 and RPA14 is involved in DNA repair as well as replication and transcriptional
 428 regulation of both cellular and viral DNA (10, 97). RPA has a strong affinity to single-
 429 stranded DNA (98) and was shown to be a component of Ad supported AAV2 RCs
 430 (79). Upon DNA damage, RPA32 becomes phosphorylated at several residues
 431 (reviewed in (107)). It was suggested that phosphorylation at S33 is mediated by
 432 ATR, while phosphorylation at S4/8 is mediated in a DNA-PK dependent manner (4,
 433 104). Here, we examined spatial localization of the RPA subunit RPA32 and its
 434 phosphorylation at S4/8 in infected cells. Our results show that total RPA32 is
 435 recruited into HSV-1 and AAV2 RCs (data not shown) and that its expression levels
 436 were not altered by virus infection (Fig. 6A). Western analysis of cells, productively
 437 infected with either HSV-1 or AAV2 revealed phosphorylation of RPA32 at Ser4/8
 438 only upon AAV2 replication (Fig. 6A). More precisely, RPA32-P-S4/8 clearly co-
 439 localized with approximately 70% of small and large AAV2 RCs, but only with 21% of
 440 small and 11% of large HSV-1 RCs (Fig. 6, B and C). UV-treated cells served as
 441 positive control (Fig. 6B). Moreover, accumulation of RPA32-P-S4/8 was only
 442 observed in AAV2 RCs of DNA-PKcs positive cells (Fig. 6D). In summary, these data
 443 show that co-infection with AAV2 and HSV-1 induces DNA-PKcs dependent
 444 phosphorylation of RPA32 at S4/8.

445

446

447 Discussion

448

449 In this study, we compared the phosphorylation status and spatial organization of
450 DDR proteins between cells infected with HSV-1 alone and cells co-infected with
451 HSV-1 and AAV2. Western and immunofluorescence analyses demonstrated that
452 HSV-1 and AAV2 co-infection induced a strong DDR (Table 1 and Fig. 7).
453 Specifically, HSV-1 supported AAV2 replication induced the phosphorylation of Nbs1
454 and H2AX, as well as ATM and its substrates Chk2 and p53. These responses are
455 similar to those induced by HSV-1 infection alone observed here and in previous
456 studies (13, 49, 67, 76, 81, 95). We also detected phosphorylation of ATR and
457 recruitment of pATR along with its binding partner ATRIP into HSV-1 supported
458 AAV2 RCs as well as into HSV-1 compartments; although kinase activity of ATR was
459 blocked upon HSV-1 and AAV2 replication as we did not detect phosphorylation of
460 Chk1 at the ATR target sites S317 and S345. Our results are similar to a previous
461 study showing that ATR, although recruited together with ATRIP into HSV-1 RCs, is
462 unable to activate Chk1. In addition Mohni et al. showed that, both ATR and ATRIP
463 even if not activated contribute to efficient HSV-1 infection (58).

464 Due to the strong affinity of RPA32 to single-stranded DNA (102, 107) and its
465 function in recruiting the ATRIP-ATR complex to sites of DNA damage (7, 26, 106), it
466 is not surprising that we and others (65, 79) detected RPA32 in HSV-1 supported
467 AAV2 RCs. In HSV-1 infected cells, RPA32 co-localizes with the HSV-1 major
468 single-stranded DNA binding protein ICP8 (81) in HSV-1 RCs (82, 93). Replicating
469 HSV-1 DNA contains stretches of single stranded DNA (39) which may recruit RPA32
470 into HSV-1 RCs also independently of ICP8. Single stranded DNA binding proteins
471 such as RPA32 are proposed to stimulate AAV2 DNA replication (64, 79), e.g. by
472 protecting the single-stranded replication products from nucleases (63) and by
473 enhancing binding and nicking of Rep proteins at the replication origins (79).

474

475 HSV-1 has been demonstrated to induce the degradation of DNA-PKcs in an ICP0
476 dependent manner (48, 67). Although Western analysis of total infected cells
477 displayed a similar degradation of DNA-PKcs, in cells infected with HSV-1 or co-
478 infected with HSV-1 and AAV2, a striking difference was observed at the single cell

level as well as in cells productively infected with HSV-1 and AAV2 captured by FACS. Flow cytometry, immunofluorescence analysis, and Western analysis of sorted cells revealed an AAV2 mediated delay in the HSV-1 dependent degradation of DNA-PKcs as well as an AAV2 induced phosphorylation of DNA-PKcs. The observed discrepancy in the results obtained with Western blots of total cell lysates and analyses on the single cell level is likely due to the fact that, under the chosen experimental conditions, only approximately 10% of the cells supported AAV2 replication. In order to estimate the extent of the delay in DNA-PKcs degradation, we co-visualized DNA-PKcs and the HSV-1 immediate-early (IE) and early (E) proteins ICP0 and ICP8, respectively, which allow monitoring the progression of HSV-1 infection. While DNA-PKcs and ICP0 or ICP8 were not co-detected in cells infected with HSV-1 alone, DNA-PKcs and ICP0 or ICP8 were consistently co-detected in cells co-infected with HSV-1 and AAV2, and they co-localized with AAV2 RCs. As we did not observe an AAV2-mediated inhibition of ICP0 in this study (Fig. S1B) and in a previous study (31), we speculate that AAV2 replication can prevent the ICP0 dependent degradation of DNA-PKcs (48, 67) e.g. by shielding DNA-PKcs in viral RCs. We can exclude the possibility, that AAV2 replication directly inhibits the E3 ubiquitin ligase activity of ICP0 because USP7, another target of ICP0-mediated proteasomal degradation (12), was rapidly degraded in co-infected cells. In addition, we can exclude a possible role of USP7 in preventing degradation of DNA-PKcs by deubiquitinating (45) DNA-PKcs. Experiments performed with ATM-deficient cells revealed that the AAV2 mediated delay of DNA-PKcs degradation affected downstream signaling via Chk2 and p53. In these cells, co-infection with both viruses resulted in a DDR comparable to that induced by infection with HSV-1 Δ ICP0, including phosphorylation of p53. Consistent with previous data (51, 76), infection of ATM-deficient cells with HSV-1 alone resulted in a broad reduction of DDR signaling with undetectable levels of Chk2-P-T86 and p53-P-S15. We therefore hypothesize that in co-infected ATM-deficient cells, DNA-PK is responsible for the phosphorylation of Chk2 and p53 (Fig. 7). A role for DNA-PK in the phosphorylation of Chk2 and p53 has previously been reported (49, 50, 85, 86, 88). In fact, here, we demonstrate that DNA-PK is essential for the activation of p53 in cells infected with AAV2 alone (Figs. 1C and 5A).

512 Recently, we reported hyperphosphorylation of RPA32 at the DNA-PK target-site
 513 S4/8 in cells transfected with plasmids encoding the AAV2 Rep68 or Rep78 proteins
 514 (30). In the present study, we detected phosphorylation of RPA32 at S4/8 and
 515 recruitment of RPA32-P-S4/8 into HSV-1 supported AAV2 RCs. In contrast, HSV-1
 516 infection alone did not induce phosphorylation of RPA32 at S4/8. Similar to the
 517 phosphorylation of Chk2 and p53 in co-infected cells, phosphorylation of RPA32 at
 518 S4/8 may also be a consequence of the delayed degradation of DNA-PKcs. Further
 519 support for this theory comes from the fact that DNA-PK has previously been
 520 demonstrated to phosphorylate RPA32 at S4/8 (4, 11, 104).

521

522 By comparing our results in co-infected cells with previous studies examining the
 523 DDR signaling in cells infected with HSV-1 alone (13, 51, 76, 96), Ad2 alone (17, 78)
 524 or co-infected with AAV2 and Ad2 (25, 75), it is remarkable that although Ad and
 525 HSV-1 by themselves induce very different DDR, in the presence of AAV2, the
 526 induction and activation pattern of DDR proteins are more similar. It seems that
 527 during AAV2 replication, the cellular DDR is modulated towards a DNA-PK-
 528 dependent signaling, which might have positive and/or negative impact on AAV
 529 replication and transduction, depending on the cellular environment and the viral
 530 genome structure (23, 25, 75). Further experiments will address the question
 531 whether this modulation can enhance HSV-1 supported AAV2 replication and/or
 532 inhibit helper virus replication.

533 **Acknowledgments**

534

535 We thank P. Beard (ETH, Lausanne, Switzerland) for helpful discussions and A.
 536 Nicolas (INSERM, Lyon, France) for critically reading the manuscript. We are also
 537 grateful to E. Hendrickson, T. Melendy, Y. Shiloh, and P. Nghiem for providing cell
 538 lines and B. Roizman, N. Stow, R.D. Everett, H. Buening, U. Greber, and M. Linden
 539 for providing viruses. This work was supported by the Swiss National Science
 540 Foundation grant No.31003A_124938 to C.F. D.L.G. is supported by fellowships
 541 from the Swiss National Science Foundation and the Swiss Foundation for Grants in
 542 Biology and Medicine (PBZHP3-122925 and PASMP3-132554). A.S. and N.J. are
 543 supported by INSERM and the Association Française contre les Myopathies (AFM).
 544 Work in the Weitzman laboratory was partially supported by a Pioneer
 545 Developmental Chair from the Salk Institute and by NIH grants CA97093 and
 546 AI43341 (M.D.W.).

547

548

References

1. **Adeyemi, R. O., S. Landry, M. E. Davis, M. D. Weitzman, and D. J. Pintel.** 2010. Parvovirus minute virus of mice induces a DNA damage response that facilitates viral replication. *PLoS Pathog* **6**:e1001141.
2. **Ahn, J. Y., J. K. Schwarz, H. Piwnica-Worms, and C. E. Canman.** 2000. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. *Cancer Res* **60**:5934-6.
3. **Alazard-Dany, N., A. Nicolas, A. Ploquin, R. Strasser, A. Greco, A. L. Epstein, C. Fraefel, and A. Salvetti.** 2009. Definition of herpes simplex virus type 1 helper activities for adeno-associated virus early replication events. *PLoS Pathog* **5**:e1000340.
4. **Anantha, R. W., V. M. Vassin, and J. A. Borowiec.** 2007. Sequential and synergistic modification of human RPA stimulates chromosomal DNA repair. *J Biol Chem* **282**:35910-23.
5. **Antoni, B. A., A. B. Rabson, I. L. Miller, J. P. Trempe, N. Chejanovsky, and B. J. Carter.** 1991. Adeno-associated virus Rep protein inhibits human immunodeficiency virus type 1 production in human cells. *J Virol* **65**:396-404.
6. **Bakkenist, C. J., and M. B. Kastan.** 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. *Nature* **421**:499-506.
7. **Ball, H. L., J. S. Myers, and D. Cortez.** 2005. ATRIP binding to replication protein A-single-stranded DNA promotes ATR-ATRIP localization but is dispensable for Chk1 phosphorylation. *Mol Biol Cell* **16**:2372-81.
8. **Banin, S., L. Moyal, S. Shieh, Y. Taya, C. W. Anderson, L. Chessa, N. I. Smorodinsky, C. Prives, Y. Reiss, Y. Shiloh, and Y. Ziv.** 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. *Science* **281**:1674-7.
9. **Berthet, C., K. Raj, P. Saudan, and P. Beard.** 2005. How adeno-associated virus Rep78 protein arrests cells completely in S phase. *Proc Natl Acad Sci U S A* **102**:13634-9.
10. **Binz, S. K., A. M. Sheehan, and M. S. Wold.** 2004. Replication protein A phosphorylation and the cellular response to DNA damage. *DNA Repair (Amst)* **3**:1015-24.
11. **Block, W. D., Y. Yu, and S. P. Lees-Miller.** 2004. Phosphatidyl inositol 3-kinase-like serine/threonine protein kinases (PIKKs) are required for DNA damage-induced phosphorylation of the 32 kDa subunit of replication protein A at threonine 21. *Nucleic Acids Res* **32**:997-1005.
12. **Boutell, C., M. Canning, A. Orr, and R. D. Everett.** 2005. Reciprocal activities between herpes simplex virus type 1 regulatory protein ICP0, a ubiquitin E3 ligase, and ubiquitin-specific protease USP7. *J Virol* **79**:12342-54.
13. **Boutell, C., and R. D. Everett.** 2004. Herpes simplex virus type 1 infection induces the stabilization of p53 in a USP7- and ATM-independent manner. *J Virol* **78**:8068-77.
14. **Buller, R. M., J. E. Janik, E. D. Sebring, and J. A. Rose.** 1981. Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus

- 597 replication. *J Virol* **40**:241-7.
- 598 15. **Burma, S., B. P. Chen, and D. J. Chen.** 2006. Role of non-homologous end
599 joining (NHEJ) in maintaining genomic integrity. *DNA Repair (Amst)* **5**:1042-8.
- 600 16. **Cahill, D., B. Connor, and J. P. Carney.** 2006. Mechanisms of eukaryotic
601 DNA double strand break repair. *Front Biosci* **11**:1958-76.
- 602 17. **Carson, C. T., R. A. Schwartz, T. H. Stracker, C. E. Lilley, D. V. Lee, and M.**
603 **D. Weitzman.** 2003. The Mre11 complex is required for ATM activation and
604 the G2/M checkpoint. *Embo J* **22**:6610-20.
- 605 18. **Cataldi, M. P., and D. M. McCarty.** 2010. Differential effects of DNA double-
606 strand break repair pathways on single-strand and self-complementary adeno-
607 associated virus vector genomes. *J Virol* **84**:8673-82.
- 608 19. **Chan, D. W., B. P. Chen, S. Prithivirajasingh, A. Kurimasa, M. D. Story, J.**
609 **Qin, and D. J. Chen.** 2002. Autophosphorylation of the DNA-dependent
610 protein kinase catalytic subunit is required for rejoining of DNA double-strand
611 breaks. *Genes Dev* **16**:2333-8.
- 612 20. **Chaturvedi, P., W. K. Eng, Y. Zhu, M. R. Mattern, R. Mishra, M. R. Hurle, X.**
613 **Zhang, R. S. Annan, Q. Lu, L. F. Faucette, G. F. Scott, X. Li, S. A. Carr, R.**
614 **K. Johnson, J. D. Winkler, and B. B. Zhou.** 1999. Mammalian Chk2 is a
615 downstream effector of the ATM-dependent DNA damage checkpoint
616 pathway. *Oncogene* **18**:4047-54.
- 617 21. **Chen, B. P., D. W. Chan, J. Kobayashi, S. Burma, A. Asaithamby, K.**
618 **Morotomi-Yano, E. Botvinick, J. Qin, and D. J. Chen.** 2005. Cell cycle
619 dependence of DNA-dependent protein kinase phosphorylation in response to
620 DNA double strand breaks. *J Biol Chem* **280**:14709-15.
- 621 22. **Chen, Y., and Y. Sanchez.** 2004. Chk1 in the DNA damage response:
622 conserved roles from yeasts to mammals. *DNA Repair (Amst)* **3**:1025-32.
- 623 23. **Choi, Y. K., K. Nash, B. J. Byrne, N. Muzyczka, and S. Song.** 2010. The
624 effect of DNA-dependent protein kinase on adeno-associated virus replication.
625 *PLoS One* **5**:e15073.
- 626 24. **Clarke, P. R., and L. A. Allan.** 2009. Cell-cycle control in the face of damage-
627 -a matter of life or death. *Trends Cell Biol* **19**:89-98.
- 628 25. **Collaco, R. F., J. M. Bevington, V. Bhargu, V. Kalman-Maltese, and J. P.**
629 **Trempe.** 2009. Adeno-associated virus and adenovirus coinfection induces a
630 cellular DNA damage and repair response via redundant phosphatidylinositol
631 3-like kinase pathways. *Virology* **392**:24-33.
- 632 26. **Dart, D. A., K. E. Adams, I. Akerman, and N. D. Lakin.** 2004. Recruitment of
633 the cell cycle checkpoint kinase ATR to chromatin during S-phase. *J Biol*
634 *Chem* **279**:16433-40.
- 635 27. **Daya, S., N. Cortez, and K. I. Berns.** 2009. Adeno-associated virus site-
636 specific integration is mediated by proteins of the nonhomologous end-joining
637 pathway. *J Virol* **83**:11655-64.
- 638 28. **Fraefel, C., A. G. Bittermann, H. Bueler, I. Heid, T. Bachi, and M.**
639 **Ackermann.** 2004. Spatial and temporal organization of adeno-associated
640 virus DNA replication in live cells. *J Virol* **78**:389-98.
- 641 29. **Giglia-Mari, G., A. Zotter, and W. Vermeulen.** 2010. DNA damage response.
642 *Cold Spring Harb Perspect Biol* **3**:a000745.
- 643 30. **Glauser, D. L., M. Seyffert, R. Strasser, M. Franchini, A. S. Laimbacher, C.**
644 **Dresch, A. P. de Oliveira, R. Vogel, H. Buning, A. Salvetti, M. Ackermann,**
645 **and C. Fraefel.** 2010. Inhibition of herpes simplex virus type 1 replication by

- 646 adeno-associated virus rep proteins depends on their combined DNA-binding
647 and ATPase/helicase activities. *J Virol* **84**:3808-24.
- 648 31. **Glauser, D. L., R. Strasser, A. S. Laimbacher, O. Saydam, N. Clement, R.**
649 **M. Linden, M. Ackermann, and C. Fraefel.** 2007. Live covisualization of
650 competing adeno-associated virus and herpes simplex virus type 1 DNA
651 replication: molecular mechanisms of interaction. *J Virol* **81**:4732-43.
- 652 32. **Guo, Z., A. Kumagai, S. X. Wang, and W. G. Dunphy.** 2000. Requirement
653 for Atr in phosphorylation of Chk1 and cell cycle regulation in response to DNA
654 replication blocks and UV-damaged DNA in *Xenopus* egg extracts. *Genes Dev*
655 **14**:2745-56.
- 656 33. **Harper, J. W., and S. J. Elledge.** 2007. The DNA damage response: ten
657 years after. *Mol Cell* **28**:739-45.
- 658 34. **Heilbronn, R., A. Burkle, S. Stephan, and H. zur Hausen.** 1990. The adeno-
659 associated virus rep gene suppresses herpes simplex virus-induced DNA
660 amplification. *J Virol* **64**:3012-8.
- 661 35. **Heilbronn, R., M. Engstler, S. Weger, A. Krahn, C. Schetter, and M.**
662 **Boshart.** 2003. ssDNA-dependent colocalization of adeno-associated virus
663 Rep and herpes simplex virus ICP8 in nuclear replication domains. *Nucleic*
664 *Acids Res* **31**:6206-13.
- 665 36. **Helleday, T., J. Lo, D. C. van Gent, and B. P. Engelward.** 2007. DNA
666 double-strand break repair: from mechanistic understanding to cancer
667 treatment. *DNA Repair (Amst)* **6**:923-35.
- 668 37. **Hunter, L. A., and R. J. Samulski.** 1992. Colocalization of adeno-associated
669 virus Rep and capsid proteins in the nuclei of infected cells. *J Virol* **66**:317-24.
- 670 38. **Jackson, S. P., and J. Bartek.** 2009. The DNA-damage response in human
671 biology and disease. *Nature* **461**:1071-8.
- 672 39. **Jacob, R. J., and B. Roizman.** 1977. Anatomy of herpes simplex virus DNA
673 VIII. Properties of the replicating DNA. *J Virol* **23**:394-411.
- 674 40. **Jing, X. J., V. Kalman-Maltese, X. Cao, Q. Yang, and J. P. Trempe.** 2001.
675 Inhibition of adenovirus cytotoxicity, replication, and E2a gene expression by
676 adeno-associated virus. *Virology* **291**:140-51.
- 677 41. **Jurvansuu, J., K. Raj, A. Stasiak, and P. Beard.** 2005. Viral transport of
678 DNA damage that mimics a stalled replication fork. *J Virol* **79**:569-80.
- 679 42. **Kastan, M. B., and D. S. Lim.** 2000. The many substrates and functions of
680 ATM. *Nat Rev Mol Cell Biol* **1**:179-86.
- 681 43. **Kastan, M. B., D. S. Lim, S. T. Kim, B. Xu, and C. Canman.** 2000. Multiple
682 signaling pathways involving ATM. *Cold Spring Harb Symp Quant Biol* **65**:521-
683 6.
- 684 44. **Kleinschmidt, J. A., M. Mohler, F. W. Weindler, and R. Heilbronn.** 1995.
685 Sequence elements of the adeno-associated virus rep gene required for
686 suppression of herpes-simplex-virus-induced DNA amplification. *Virology*
687 **206**:254-62.
- 688 45. **Komander, D., M. J. Clague, and S. Urbe.** 2009. Breaking the chains:
689 structure and function of the deubiquitinases. *Nat Rev Mol Cell Biol* **10**:550-63.
- 690 46. **Lakin, N. D., B. C. Hann, and S. P. Jackson.** 1999. The ataxia-telangiectasia
691 related protein ATR mediates DNA-dependent phosphorylation of p53.
692 *Oncogene* **18**:3989-95.
- 693 47. **Lamarche, B. J., N. I. Orazio, and M. D. Weitzman.** 2010. The MRN complex
694 in double-strand break repair and telomere maintenance. *FEBS Lett*

- 695 584:3682-95.
- 696 48. **Lees-Miller, S. P., M. C. Long, M. A. Kilvert, V. Lam, S. A. Rice, and C. A.**
- 697 **Spencer.** 1996. Attenuation of DNA-dependent protein kinase activity and its
- 698 catalytic subunit by the herpes simplex virus type 1 transactivator ICP0. *J Virol*
- 699 **70:7471-7.**
- 700 49. **Lees-Miller, S. P., K. Sakaguchi, S. J. Ullrich, E. Appella, and C. W.**
- 701 **Anderson.** 1992. Human DNA-activated protein kinase phosphorylates
- 702 serines 15 and 37 in the amino-terminal transactivation domain of human p53.
- 703 *Mol Cell Biol* **12:5041-9.**
- 704 50. **Li, J., and D. F. Stern.** 2005. Regulation of CHK2 by DNA-dependent protein
- 705 kinase. *J Biol Chem* **280:12041-50.**
- 706 51. **Lilley, C. E., C. T. Carson, A. R. Muotri, F. H. Gage, and M. D. Weitzman.**
- 707 2005. DNA repair proteins affect the lifecycle of herpes simplex virus 1. *Proc*
- 708 *Natl Acad Sci U S A* **102:5844-9.**
- 709 52. **Linden, R. M., and K. I. Berns.** 2000. Molecular biology of adeno-associated
- 710 viruses. *Contrib Microbiol* **4:68-84.**
- 711 53. **Liu, Q., S. Guntuku, X. S. Cui, S. Matsuoka, D. Cortez, K. Tamai, G. Luo,**
- 712 **S. Carattini-Rivera, F. DeMayo, A. Bradley, L. A. Donehower, and S. J.**
- 713 **Elledge.** 2000. Chk1 is an essential kinase that is regulated by Atr and
- 714 required for the G(2)/M DNA damage checkpoint. *Genes Dev* **14:1448-59.**
- 715 54. **Liu, S., B. Shiotani, M. Lahiri, A. Marechal, A. Tse, C. C. Leung, J. N.**
- 716 **Glover, X. H. Yang, and L. Zou.** ATR autophosphorylation as a molecular
- 717 switch for checkpoint activation. *Mol Cell* **43:192-202.**
- 718 55. **Lovejoy, C. A., and D. Cortez.** 2009. Common mechanisms of PIKK
- 719 regulation. *DNA Repair (Amst)* **8:1004-8.**
- 720 56. **Matsuoka, S., M. Huang, and S. J. Elledge.** 1998. Linkage of ATM to cell
- 721 cycle regulation by the Chk2 protein kinase. *Science* **282:1893-7.**
- 722 57. **Matsuoka, S., G. Rotman, A. Ogawa, Y. Shiloh, K. Tamai, and S. J.**
- 723 **Elledge.** 2000. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and
- 724 in vitro. *Proc Natl Acad Sci U S A* **97:10389-94.**
- 725 58. **Mohni, K. N., C. M. Livingston, D. Cortez, and S. K. Weller.** 2010. ATR and
- 726 ATRIP are recruited to herpes simplex virus type 1 replication compartments
- 727 even though ATR signaling is disabled. *J Virol* **84:12152-64.**
- 728 59. **Mordes, D. A., and D. Cortez.** 2008. Activation of ATR and related PIKKs.
- 729 *Cell Cycle* **7:2809-12.**
- 730 60. **Morio, T., and H. Kim.** 2008. Ku, Artemis, and ataxia-telangiectasia-mutated:
- 731 signalling networks in DNA damage. *Int J Biochem Cell Biol* **40:598-603.**
- 732 61. **Nada, S., and J. P. Trempe.** 2002. Characterization of adeno-associated virus
- 733 rep protein inhibition of adenovirus E2a gene expression. *Virology* **293:345-**
- 734 **55.**
- 735 62. **Nam, E. A., and D. Cortez.** ATR signalling: more than meeting at the fork.
- 736 *Biochem J* **436:527-36.**
- 737 63. **Nash, K., W. Chen, M. Salganik, and N. Muzyczka.** 2009. Identification of
- 738 cellular proteins that interact with the adeno-associated virus rep protein. *J*
- 739 *Virol* **83:454-69.**
- 740 64. **Ni, T. H., W. F. McDonald, I. Zolotukhin, T. Melendy, S. Waga, B. Stillman,**
- 741 **and N. Muzyczka.** 1998. Cellular proteins required for adeno-associated virus
- 742 DNA replication in the absence of adenovirus coinfection. *J Virol* **72:2777-87.**
- 743 65. **Nicolas, A., N. Alazard-Dany, C. Biollay, L. Arata, N. Jolinon, L. Kuhn, M.**

- 744 **Ferro, S. K. Weller, A. L. Epstein, A. Salvetti, and A. Greco.** 2010.
745 Identification of Rep-Associated Factors in Hsv-1-Induced Aav-2 Replication
746 Compartments. *J Virol*.
- 747 66. **Ohnishi, T., E. Mori, and A. Takahashi.** 2009. DNA double-strand breaks:
748 their production, recognition, and repair in eukaryotes. *Mutat Res* **669**:8-12.
- 749 67. **Parkinson, J., S. P. Lees-Miller, and R. D. Everett.** 1999. Herpes simplex
750 virus type 1 immediate-early protein vmw110 induces the proteasome-
751 dependent degradation of the catalytic subunit of DNA-dependent protein
752 kinase. *J Virol* **73**:650-7.
- 753 68. **Raj, K., P. Ogston, and P. Beard.** 2001. Virus-mediated killing of cells that
754 lack p53 activity. *Nature* **412**:914-7.
- 755 69. **Reinhardt, H. C., and M. B. Yaffe.** 2009. Kinases that control the cell cycle in
756 response to DNA damage: Chk1, Chk2, and MK2. *Curr Opin Cell Biol* **21**:245-
757 55.
- 758 70. **Robinson, K., N. Asawachaicharn, D. A. Galloway, and C. Grandori.** 2009.
759 c-Myc accelerates S-Phase and requires WRN to avoid replication stress.
760 *PLoS One* **4**:e5951.
- 761 71. **Rommelaere, J., and J. J. Cornelis.** 1991. Antineoplastic activity of
762 parvoviruses. *J Virol Methods* **33**:233-51.
- 763 72. **Samulski, R. J., X. Zhu, X. Xiao, J. D. Brook, D. E. Housman, N. Epstein,**
764 **and L. A. Hunter.** 1991. Targeted integration of adeno-associated virus (AAV)
765 into human chromosome 19. *Embo J* **10**:3941-50.
- 766 73. **Saudan, P., J. Vlach, and P. Beard.** 2000. Inhibition of S-phase progression
767 by adeno-associated virus Rep78 protein is mediated by hypophosphorylated
768 pRb. *Embo J* **19**:4351-61.
- 769 74. **Schlehofer, J. R.** 1994. The tumor suppressive properties of adeno-
770 associated viruses. *Mutat Res* **305**:303-13.
- 771 75. **Schwartz, R. A., C. T. Carson, C. Schuberth, and M. D. Weitzman.** 2009.
772 Adeno-associated virus replication induces a DNA damage response
773 coordinated by DNA-dependent protein kinase. *J Virol* **83**:6269-78.
- 774 76. **Shirata, N., A. Kudoh, T. Daikoku, Y. Tatsumi, M. Fujita, T. Kiyono, Y.**
775 **Sugaya, H. Isomura, K. Ishizaki, and T. Tsurumi.** 2005. Activation of ataxia
776 telangiectasia-mutated DNA damage checkpoint signal transduction elicited by
777 herpes simplex virus infection. *J Biol Chem* **280**:30336-41.
- 778 77. **Song, S., Y. Lu, Y. K. Choi, Y. Han, Q. Tang, G. Zhao, K. I. Berns, and T. R.**
779 **Flotte.** 2004. DNA-dependent PK inhibits adeno-associated virus DNA
780 integration. *Proc Natl Acad Sci U S A* **101**:2112-6.
- 781 78. **Stracker, T. H., C. T. Carson, and M. D. Weitzman.** 2002. Adenovirus
782 oncoproteins inactivate the Mre11-Rad50-NBS1 DNA repair complex. *Nature*
783 **418**:348-52.
- 784 79. **Stracker, T. H., G. D. Cassell, P. Ward, Y. M. Loo, B. van Breukelen, S. D.**
785 **Carrington-Lawrence, R. K. Hamatake, P. C. van der Vliet, S. K. Weller, T.**
786 **Melendy, and M. D. Weitzman.** 2004. The Rep protein of adeno-associated
787 virus type 2 interacts with single-stranded DNA-binding proteins that enhance
788 viral replication. *J Virol* **78**:441-53.
- 789 80. **Tapia-Alveal, C., T. M. Calonge, and M. J. O'Connell.** 2009. Regulation of
790 chk1. *Cell Div* **4**:8.
- 791 81. **Taylor, T. J., and D. M. Knipe.** 2004. Proteomics of herpes simplex virus
792 replication compartments: association of cellular DNA replication, repair,

- 793 recombination, and chromatin remodeling proteins with ICP8. *J Virol* **78**:5856-
794 66.
- 795 82. **Taylor, T. J., E. E. McNamee, C. Day, and D. M. Knipe.** 2003. Herpes
796 simplex virus replication compartments can form by coalescence of smaller
797 compartments. *Virology* **309**:232-47.
- 798 83. **Tibbetts, R. S., D. Cortez, K. M. Brumbaugh, R. Scully, D. Livingston, S. J.**
799 **Elledge, and R. T. Abraham.** 2000. Functional interactions between BRCA1
800 and the checkpoint kinase ATR during genotoxic stress. *Genes Dev* **14**:2989-
801 3002.
- 802 84. **Timpe, J. M., K. C. Verrill, and J. P. Trempe.** 2006. Effects of adeno-
803 associated virus on adenovirus replication and gene expression during
804 coinfection. *J Virol* **80**:7807-15.
- 805 85. **Tomimatsu, N., B. Mukherjee, and S. Burma.** 2009. Distinct roles of ATR
806 and DNA-PKcs in triggering DNA damage responses in ATM-deficient cells.
807 *EMBO Rep* **10**:629-35.
- 808 86. **Wang, S., M. Guo, H. Ouyang, X. Li, C. Cordon-Cardo, A. Kurimasa, D. J.**
809 **Chen, Z. Fuks, C. C. Ling, and G. C. Li.** 2000. The catalytic subunit of DNA-
810 dependent protein kinase selectively regulates p53-dependent apoptosis but
811 not cell-cycle arrest. *Proc Natl Acad Sci U S A* **97**:1584-8.
- 812 87. **Wang, X. Q., J. L. Redpath, S. T. Fan, and E. J. Stanbridge.** 2006. ATR
813 dependent activation of Chk2. *J Cell Physiol* **208**:613-9.
- 814 88. **Wang, Y., and W. Eckhart.** 1992. Phosphorylation sites in the amino-terminal
815 region of mouse p53. *Proc Natl Acad Sci U S A* **89**:4231-5.
- 816 89. **Warmerdam, D. O., and R. Kanaar.** 2010. Dealing with DNA damage:
817 relationships between checkpoint and repair pathways. *Mutat Res* **704**:2-11.
- 818 90. **Weindler, F. W., and R. Heilbronn.** 1991. A subset of herpes simplex virus
819 replication genes provides helper functions for productive adeno-associated
820 virus replication. *J Virol* **65**:2476-83.
- 821 91. **Weitzman, M. D., K. J. Fisher, and J. M. Wilson.** 1996. Recruitment of wild-
822 type and recombinant adeno-associated virus into adenovirus replication
823 centers. *J Virol* **70**:1845-54.
- 824 92. **Weitzman, M. D., C. E. Lilley, and M. S. Chaurushiya.** 2009. Genomes in
825 conflict: maintaining genome integrity during virus infection. *Annu Rev*
826 *Microbiol* **64**:61-81.
- 827 93. **Wilcock, D., and D. P. Lane.** 1991. Localization of p53, retinoblastoma and
828 host replication proteins at sites of viral replication in herpes-infected cells.
829 *Nature* **349**:429-31.
- 830 94. **Wilkinson, D. E., and S. K. Weller.** 2006. Herpes simplex virus type I disrupts
831 the ATR-dependent DNA-damage response during lytic infection. *J Cell Sci*
832 **119**:2695-703.
- 833 95. **Wilkinson, D. E., and S. K. Weller.** 2005. Inhibition of the herpes simplex
834 virus type 1 DNA polymerase induces hyperphosphorylation of replication
835 protein A and its accumulation at S-phase-specific sites of DNA damage
836 during infection. *J Virol* **79**:7162-71.
- 837 96. **Wilkinson, D. E., and S. K. Weller.** 2004. Recruitment of cellular
838 recombination and repair proteins to sites of herpes simplex virus type 1 DNA
839 replication is dependent on the composition of viral proteins within
840 prereplicative sites and correlates with the induction of the DNA damage
841 response. *J Virol* **78**:4783-96.

- 842 97. **Wold, M. S.** 1997. Replication protein A: a heterotrimeric, single-stranded
843 DNA-binding protein required for eukaryotic DNA metabolism. *Annu Rev*
844 *Biochem* **66**:61-92.
- 845 98. **Wold, M. S., and T. Kelly.** 1988. Purification and characterization of
846 replication protein A, a cellular protein required for in vitro replication of simian
847 virus 40 DNA. *Proc Natl Acad Sci U S A* **85**:2523-7.
- 848 99. **Wyman, C., and R. Kanaar.** 2006. DNA double-strand break repair: all's well
849 that ends well. *Annu Rev Genet* **40**:363-83.
- 850 100. **Yang, Q., F. Chen, J. Ross, and J. P. Trempe.** 1995. Inhibition of cellular and
851 SV40 DNA replication by the adeno-associated virus Rep proteins. *Virology*
852 **207**:246-50.
- 853 101. **Yang, Q., F. Chen, and J. P. Trempe.** 1994. Characterization of cell lines that
854 inducibly express the adeno-associated virus Rep proteins. *J Virol* **68**:4847-
855 56.
- 856 102. **You, J. S., M. Wang, and S. H. Lee.** 2000. Functional characterization of zinc-
857 finger motif in redox regulation of RPA-ssDNA interaction. *Biochemistry*
858 **39**:12953-8.
- 859 103. **You, Z., C. Chahwan, J. Bailis, T. Hunter, and P. Russell.** 2005. ATM
860 activation and its recruitment to damaged DNA require binding to the C
861 terminus of Nbs1. *Mol Cell Biol* **25**:5363-79.
- 862 104. **Zernik-Kobak, M., K. Vasunia, M. Connelly, C. W. Anderson, and K.**
863 **Dixon.** 1997. Sites of UV-induced phosphorylation of the p34 subunit of
864 replication protein A from HeLa cells. *J Biol Chem* **272**:23896-904.
- 865 105. **Zhao, H., and H. Piwnica-Worms.** 2001. ATR-mediated checkpoint pathways
866 regulate phosphorylation and activation of human Chk1. *Mol Cell Biol*
867 **21**:4129-39.
- 868 106. **Zou, L., and S. J. Elledge.** 2003. Sensing DNA damage through ATRIP
869 recognition of RPA-ssDNA complexes. *Science* **300**:1542-8.
- 870 107. **Zou, Y., Y. Liu, X. Wu, and S. M. Shell.** 2006. Functions of human replication
871 protein A (RPA): from DNA replication to DNA damage and stress responses.
872 *J Cell Physiol* **208**:267-73.
873
874
875

876

877 **Figure legends**

878

879 **Figure 1. DNA damage signaling induced by viral infection. (A-C)** Western
880 analysis of infected cell lysates. MO59J Fus1 cells were either mock-infected (m) or
881 infected with AAV2 alone (MOI 2000), HSV-1 alone (MOI 1.5), or co-infected with
882 AAV2 (MOI 2000) and HSV-1 (MOI 1.5) and harvested at the indicated hours post
883 infection (hpi). Total proteins were extracted, separated by SDS-PAGE, blotted onto
884 nitrocellulose membrane, and analyzed with the indicated antibodies. Actin served
885 as a loading control; detection of HSV-1 ICP8 and AAV2 Rep was used as an
886 infection control.

887

888

889 **Figure 2. Activation of primary DNA damage response proteins.** MO59J Fus1
890 cells were either mock-infected or infected with HSV-1 (MOI 1.5), or co-infected with
891 rAAVCR (MOI 250) and HSV-1 (MOI 1.5). After 24 h, cells were fixed and processed
892 for immunofluorescence analysis. rAAVCR replication compartments (AAV RCs)
893 were visualized by binding of the rAAVCR encoded mCherry-Rep68/78 fusion protein
894 (CR) to AAV DNA (red). HSV-1 RCs were visualized with a primary antibody specific
895 for the HSV-1 major DNA binding protein ICP8 and an AF594-labeled secondary
896 antibody (red). Cells treated with HU (3mM) served as DDR control. To identify
897 phosphorylated Nbs1 **(A)** and H2AX **(B)**, cells were stained with antibodies specific
898 for Nbs1-P-S343 or H2AX-P-S139 (γH2AX) and a FITC-labeled secondary antibody
899 (green). DAPI was used to stain cellular DNA. Images were taken using a confocal
900 laser scanning microscope and represent a single optical z slice of the nuclei. Scale
901 bar = 10 μm.

902

903

904 **Figure 3. Recruitment of ATM-P-S1981, ATR-P-S428, and ATRIP into HSV-1 and**
905 **AAV2 RCs.** MO59J Fus1 cells were infected and processed for
906 immunofluorescence, and viral RCs (red) were visualized as described in Fig. 2.
907 Cells were stained with an antibody specific for **(A)** ATM-P-S1981, **(B)** ATR-P-S428,
908 or **(C)** ATRIP and a FITC-labeled secondary antibody (green). DAPI was used to

909 stain cell nuclei. In A, cells deficient for ATM (AT-22 IJE T) served as a control for
 910 the phosphospecific ATM-antibody. In B, the percentage of ATR-P-S428 in viral RCs
 911 is indicated. Scale bar = 10 μ m.

912

913

914 **Figure 4. Activation and delayed degradation of DNA-PKcs in cells co-infected**
 915 **with HSV-1 and AAV2. (A)** MO59J Fus1 cells were infected with HSV-1 (MOI 1.5),
 916 HSV-1 Δ ICP0 (MOI 0.9), or mock-infected. After 24 h, cells were fixed and processed
 917 for immunofluorescence analysis. HSV-1 infection was detected using an antibody
 918 specific for ICP0 or ICP8 and an AF594-labeled secondary antibody (red).
 919 Additionally, cells were stained with an antibody specific for DNA-PKcs and a FITC-
 920 labeled secondary antibody (green). DAPI was used to stain cellular DNA. Scale bar
 921 = 10 μ m. **(B)** Immunofluorescence analysis of MO59J Fus1 cells at 24 h after co-
 922 infection with rAAVCR (MOI 250) and HSV-1 (MOI 1.5). rAAVCR RCs (red) were
 923 visualized as described in Fig. 2. Additionally, cells were stained with antibodies
 924 specific for ICP0 or ICP8 and an AF405-labeled secondary antibody (purple) and with
 925 an antibody specific for DNA-PKcs and an FITC-labeled secondary antibody (green).
 926 The percentage of DNA-PKcs in rAAVCR RCs is indicated. Scale bar = 10 μ m. **(C)**
 927 Flow cytometric analysis of infected cells. DNA-PKcs positive HCT116 cells were
 928 mock infected (positive control), infected with rHSV-1ICP4eYFP (MOI 1.5) or co-
 929 infected with HSV-1 (MOI 1.5), AAV2 (MOI 250), and rAAVGFP (MOI 250). HCT116
 930 cells negative for DNA-PKcs, served as negative control. Cells were fixed 20 h post-
 931 infection and stained with a monoclonal DNA-PKcs-specific antibody and a Cy5-
 932 labeled secondary antibody. DNA-PKcs was analyzed in HSV-1-infected cells
 933 positive for EYFP-ICP4 (HSV) and in co-infected cells positive for EGFP (HSV+AAV).
 934 A minimum of 80'0000 events were scored for each sample. Graphs were overlayed
 935 to show the fluorescence shift of HSV-1 infected populations. **(D and E)** Western
 936 analysis of AT22IJE-T cells, sorted for productive HSV-1 and AAV2 infection at 22
 937 and 26 hpi. Cells were mock-infected, infected with rHSV-1vECFP-ICP4 (rHSV; MOI
 938 2), or co-infected (rHSV + rAAV) with rHSV-1vECFP-ICP4 (MOI 2) and rAAV2CR
 939 (MOI 4000). Lysates of sorted cells were processed for Western analysis and
 940 stained with the indicated antibodies. Quantification of Western blot band intensities
 941 was done with a gel doc system using Quantity One® software (Version 4.6.1;

942 BioRad; Hercules; CA; USA). **(F)** Western analysis of AT22IJE-T cells, sorted for
 943 productive HSV-1 and AAV2 infection at 24hpi. Cells were mock-infected, infected
 944 with rHSV-1vECFP-ICP4 (rHSV; MOI 4), or co-infected (rHSV + rAAV) with rHSV-
 945 1vECFP-ICP4 (MOI 4) and rAAV2CR (MOI 4000). Lysates of sorted cells were
 946 processed for Western analysis and stained with the indicated antibodies. **(G)**
 947 MO59J Fus1 cells were mock-infected, infected with HSV-1 (MOI 1.5), or co-infected
 948 with rAAVCR (MOI 250) and either HSV-1 (MOI 1.5) or Ad2 (MOI 12.5). After 24 h,
 949 cells were fixed and processed for immunofluorescence analysis. rAAVCR and HSV-
 950 1 RCs (red) were visualized as described in Fig. 2. DNA-PKcs-phosphorylation was
 951 detected with an antibody specific for DNA-PKcs-P-S2056 and a FITC-labeled
 952 secondary antibody (green). As negative control, MO59J Fus9 DNA-PKcs-negative
 953 cells were co-infected with rAAVCR (MOI 250) and Ad2 (MOI 12.5) and stained for
 954 pDNA-PKcs. DAPI was used to stain cellular DNA. Scale bar = 10 μ m.

955
 956

957 **Figure 5. DNA-PKcs and ATM dependent activation of Chk2 and p53 upon viral**
 958 **infection. (A)** Western analysis of DNA-PKcs-deficient MO59J Fus9 cells. Cells
 959 were mock-infected or infected with AAV2 (MOI 2000), HSV-1 (MOI 1.5), or co-
 960 infected with AAV2 (MOI 2000) and HSV-1 (MOI 1.5). Total proteins were extracted
 961 at the indicated hpi and subjected to Western analysis using antibodies specific for
 962 actin (loading control), ICP8 (HSV-1 infection control), Chk2, Chk2-P-T68, and p53-
 963 P-S15. **(B)** Immunoprecipitation and Western analysis of ATM-negative AT22 IJE-T
 964 cells at 24 h after mock-infection (m) or infection with AAV2 (MOI 2000), HSV-1 (MOI
 965 1.5), AAV2 (MOI 2000) and HSV-1 (MOI 1.5). Lysates were analyzed using the
 966 indicated antibodies. **(C)** Immunofluorescence analysis of ATM-negative AT22 IJE-T
 967 cells at 24 h after infection with HSV-1 (MOI 1.5), rAAVCR (MOI 250) and HSV-1
 968 (MOI 1.5), HSV-1 Δ ICP0 (MOI 0.9), or mock-infection. rAAVCR and HSV-1 RCs (red)
 969 were visualized as described in Fig. 2. p53-activation was detected with an antibody
 970 specific for p53-P-S15 and an FITC-labeled secondary antibody (green). DAPI was
 971 used to stain cellular nuclei. Scale bar = 10 μ m.

972
 973

974 **Figure 6. Phosphorylation of RPA32 upon AAV2 and HSV-1 replication. (A)**

975 Western analysis of sorted AT221JE-T cells at 24 hpi. Cells were mock-infected,
 976 infected with rHSV-1vECFP-ICP4 (rHSV; MOI 4), or co-infected (rHSV + rAAV) with
 977 rHSV-1vECFP-ICP4 (MOI 4) and rAAV2CR (MOI 4000). Sorted cells were subjected
 978 to Western analysis and analyzed with the indicated antibodies. **(B)**
 979 Immunofluorescence analysis of U2OS cells after infection with HSV-1 (MOI 1.5),
 980 rAAVCR (MOI 250) and HSV-1 (MOI 1.5), or mock-infection at 24 h. UV-treated cells
 981 ($10\text{J}/\text{m}^2$) served as positive control. rAAVCR and HSV-1 RCs (red) were visualized
 982 as described in Fig. 2. To detect phosphorylated RPA32, cells were stained with an
 983 antibody specific for RPA32-P-S4/8 and a FITC-labeled secondary antibody (green).
 984 Cellular DNA was stained with DAPI. Scale bar = 10 μm . **(C)** Quantification of
 985 RPA32-P-S4/8 co-localization with small and large AAV2 or HSV-1 RCs in U2OS
 986 cells. 50 cells per sample were counted. Black columns, RPA32-P-S4/8 positive
 987 viral RCs; open columns, RPA32-P-S4/8 negative viral RCs **(D)** Immunofluorescence
 988 analysis of MO59J Fus1 or Fus9 (DNA-PKcs-negative) cells at 24 h after mock-
 989 infection or co-infection with HSV-1 (MOI 1.5) and rAAVCR (MOI 250). rAAVCR RCs
 990 (red) were visualized as described in Fig. 2. Cells were stained with an antibody
 991 specific for RPA32-P-S4/8 and an Alexa Fluor405-labeled secondary antibody (blue).
 992 Scale bar = 10 μm .

993
 994
 995 **Figure 7. Models for the DDR signaling induced by HSV-1 replication and HSV-**
 996 **1 supported AAV replication.** The analysis of the DDR in ATM-deficient-, DNA-
 997 PKcs-deficient- and normal cells support the following models: Infection of cells with
 998 HSV-1 induces phosphorylation of ATM and ATR, and signaling to their targets Nbs1,
 999 H2AX, Chk2, p53, but not to the ATR-target Chk1. In cells infected with HSV-1
 1000 alone, DNA-PKcs is rapidly degraded in an HSV-1 ICP0 dependent manner, and no
 1001 DNA-PKcs-mediated signaling occurs. By contrast, co-infection with HSV-1 and
 1002 AAV2 induces the activation of DNA-PKcs which enables phosphorylation of RPA32
 1003 at S4/8. Further support for the activation of DNA-PKcs in co-infected cells comes
 1004 from experiments performed in ATM-deficient cells, as in absence of ATM, HSV-1
 1005 and AAV2 co-infection still induced the phosphorylation of p53, Chk2, and RPA32 at
 1006 S4/8. In ATM-deficient cells infected with HSV-1 alone, the DDR signaling is broadly
 1007 reduced with undetectable levels of Chk2-P-T86 and p53-P-S15 (Lilley et al., 2005;

1008 Shirata et al., 2007).

Vogel et al., Table 1


TABLE 1. **DNA damage signaling in cells infected with HSV-1 or co-infected with HSV-1 and (r)AAV2.**

Summary of data from Western analysis, immunofluorescence analysis, and flow cytometry.

Protein	HSV-1 and (r)AAV2 co-infection				HSV-1 infection			
	Inhibition	Induction	Phosph.	Local.	Inhibition	Induction	Phosph.	Local.
ATM	-	-	+	NUC+RCs	-	-	+	RCs
ATR	-	-	+	RCs	-	-	+	RCs
ATRIP	-	+	nd	RCs	-	+	nd	RCs
DNA-PKcs	+^a	-	+	RCs	+	-	-	-
USP7	+	-	nd	RCs	+	-	nd	nd
H2AX	nd	nd	+	NUC	nd	nd	+	NUC
NBS1	-	-	+	RCs	-	-	+	RCs
RPA32 (P-Ser4/8)	-	-	+	RCs	-	-	-	RCs
p53	-	+	+	RCs	-	+	+	RCs
Chk1	-	-	-	RCs	-	-	-	RCs
Chk2	-	-	+	RCs	-	-	+	RCs


^a Inhibition delayed; NUC, nucleus; nd, not done; bold, AAV-induced modulation of DDR.

Vogel et al., Fig. 1




Vogel et al., Fig. 2

A




Vogel et al., Fig. 2

B




Vogel et al., Fig. 3

A




Vogel et al., Fig. 3

B




C




Vogel et al., Fig. 4

A




Vogel et al., Fig. 4


B




C




Vogel et al., Fig. 4




G



Vogel et al., Fig. 5




Vogel et al., Fig. 6



Vogel et al., Fig. 6

C



D

